Shilpa Medicare to participate in Nuvama CEO Forum on Sep 28, 2026

0 min read | Published on 22 Sept 2026, 04:05 PM |Updated on 22 Sept 2026, 04:05 PM

Reviewed by

Jubin VScanX News Team

Add as a preferred
source on Google

Key Highlights

Shilpa Medicare officials will attend the Nuvama Emerging India CEO Forum on September 28, 2026
Meetings in Mumbai will include both one-on-one and group sessions with investors
The company confirmed that no Unpublished Price Sensitive Information will be disclosed
Participation is reported under SEBI Listing Regulations for investor conferences

*this image is generated using AI for illustrative purposes only.

Shilpa Medicare Limited announced that its officials will participate in the Nuvama Emerging India CEO Forum in Mumbai on September 28, 2026. The event provides an opportunity for one-on-one and group meetings with investors and analysts.

The participation is disclosed under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates timely disclosure of material events to ensure market transparency.

Meeting Details

The company outlined the specific parameters of the upcoming engagement in its filing to stock exchanges.

Parameter	Detail
Date	September 28, 2026
Event	Nuvama Emerging India CEO Forum
Location	Mumbai
Meeting Type	In Person
Format	1x1 and Group Meetings

Disclosure Compliance

Shilpa Medicare stated that no Unpublished Price Sensitive Information (UPSI) will be shared during these meetings. The company noted that the schedule remains subject to change by the organizers, investors, or the company itself.

This intimation was filed with BSE Limited and National Stock Exchange of India Limited on September 22, 2026.

Historical Stock Returns for Shilpa Medicare

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.52%	+7.49%	+26.77%	+219.61%	+150.46%	+273.05%

How might the insights shared at the Nuvama Emerging India CEO Forum influence Shilpa Medicare's upcoming quarterly guidance?

What specific strategic priorities is Shilpa Medicare expected to highlight to institutional investors regarding its API segment growth?

Will the engagement with analysts lead to any revisions in consensus earnings estimates for Shilpa Medicare in the near term?

Shilpa Medicare

View Company Insights

View All News

Shilpa Medicare's Hyderabad unit gets one remark in USFDA inspection

0 min read | Published on 18 Sept 2026, 07:40 PM |Updated on 21 Sept 2026, 05:37 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

Shilpa Medicare's Hyderabad unit underwent a USFDA surveillance inspection
The facility received one procedural observation during the review
The finding relates to a process-level issue at the Analytical Services Division
Standard regulatory procedure requires submission of a corrective action plan

*this image is generated using AI for illustrative purposes only.

Shilpa Medicare 's Hyderabad facility received one process observation following a USFDA inspection.

Inspection outcome

The USFDA conducted a surveillance inspection at Shilpa Medicare's Hyderabad Analytical Services Division, concluding with the issuance of one procedural observation. Such observations are part of the standard regulatory review process conducted by the US Food and Drug Administration at pharmaceutical manufacturing sites.

Parameter	Details
Facility location	Hyderabad (Analytical Services Division)
Inspecting authority	USFDA
Inspection type	Surveillance
Number of observations	One procedural remark

The single observation noted during the inspection relates to a process-level finding at the facility. Companies typically respond to such remarks by submitting a corrective action plan to the USFDA within the stipulated timeframe.

Historical Stock Returns for Shilpa Medicare

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-3.52%	+7.49%	+26.77%	+219.61%	+150.46%	+273.05%

Disclaimer: This article is AI-generated using data from LiveSquawk. ScanX is not liable for any inaccuracies.

How might this procedural observation impact Shilpa Medicare's timeline for submitting its corrective action plan to the USFDA?

What are the potential implications for Shilpa Medicare's export approvals or existing contracts with US-based clients if the observation is not resolved swiftly?

How does this single observation compare to the regulatory inspection history of other major Indian generic pharmaceutical manufacturers in recent quarters?

Shilpa Medicare

View Company Insights

View All News